Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

April Armstrong

Showing results (81-90 of 124) with videos related to

Pageof 13
Sort By:
Dermatologic Therapy|October 21, 2022
Baricitinib 2 mg for the treatment of atopic dermatitis in North America: Long-term efficacy and patient-reported outcomesEric Simpson, April Armstrong, Mark Boguniewicz, et al.
Journal of Drugs in Dermatology : JDD|May 6, 2024
Patient- and Clinician-Reported Outcomes for Tirbanibulin in Actinic Keratosis in Clinical Practice Across the United States (PROAK)Todd Schlesinger, Leon Kircik, Mark Lebwohl, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 5, 2024
Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial)Bruce Strober, Hervé Bachelez, Jeffrey Crowley, et al.
Journal of the American Academy of Dermatology|April 8, 2024
Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trialsMark Lebwohl, Joseph F Merola, Bruce Strober, et al.
Dermatology and Therapy|December 8, 2025
Bimekizumab Impact on Patient-Reported Outcomes in Plaque Psoriasis: 4-Year Results from BE SURE, BE VIVID, BE READY, and BE BRIGHTApril Armstrong, Kim A Papp, Mark Lebwohl, et al.
Dermatology and Therapy|August 6, 2025
Benefits of Earlier Apremilast Initiation in Patients with Psoriasis and Limited Skin Involvement: Results from a Real-World Retrospective StudyApril Armstrong, Bruce Strober, Paolo Gisondi, et al.
Dermatology and Therapy|June 26, 2024
Lebrikizumab Improves Quality of Life and Patient-Reported Symptoms of Anxiety and Depression in Patients with Moderate-to-Severe Atopic DermatitisPeter A Lio, April Armstrong, Jan Gutermuth, et al.
Dermatology (Basel, Switzerland)|October 30, 2024
Efficacy and Safety of Upadacitinib versus Dupilumab Treatment for Moderate-to-Severe Atopic Dermatitis in Four Body Regions: Analysis from the Heads Up StudyJacob P Thyssen, David Rosmarin, Antonio Costanzo, et al.
Dermatology and Therapy|July 7, 2022
Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-AnalysisApril Armstrong, Kyle Fahrbach, Craig Leonardi, et al.
JAAD International|July 23, 2024
Developing a questionnaire for assessing clinician- and patient-reported outcomes in actinic keratosis: Results from an expert panelBrian Berman, April Armstrong, Mark Lebwohl, et al.
Pageof 13

Showing results (81-90 of 124) with videos related to

Sort By:
Pageof 13
Dermatologic Therapy|October 21, 2022
Baricitinib 2 mg for the treatment of atopic dermatitis in North America: Long-term efficacy and patient-reported outcomesEric Simpson, April Armstrong, Mark Boguniewicz, et al.
Journal of Drugs in Dermatology : JDD|May 6, 2024
Patient- and Clinician-Reported Outcomes for Tirbanibulin in Actinic Keratosis in Clinical Practice Across the United States (PROAK)Todd Schlesinger, Leon Kircik, Mark Lebwohl, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 5, 2024
Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial)Bruce Strober, Hervé Bachelez, Jeffrey Crowley, et al.
Journal of the American Academy of Dermatology|April 8, 2024
Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trialsMark Lebwohl, Joseph F Merola, Bruce Strober, et al.
Dermatology and Therapy|December 8, 2025
Bimekizumab Impact on Patient-Reported Outcomes in Plaque Psoriasis: 4-Year Results from BE SURE, BE VIVID, BE READY, and BE BRIGHTApril Armstrong, Kim A Papp, Mark Lebwohl, et al.
Dermatology and Therapy|August 6, 2025
Benefits of Earlier Apremilast Initiation in Patients with Psoriasis and Limited Skin Involvement: Results from a Real-World Retrospective StudyApril Armstrong, Bruce Strober, Paolo Gisondi, et al.
Dermatology and Therapy|June 26, 2024
Lebrikizumab Improves Quality of Life and Patient-Reported Symptoms of Anxiety and Depression in Patients with Moderate-to-Severe Atopic DermatitisPeter A Lio, April Armstrong, Jan Gutermuth, et al.
Dermatology (Basel, Switzerland)|October 30, 2024
Efficacy and Safety of Upadacitinib versus Dupilumab Treatment for Moderate-to-Severe Atopic Dermatitis in Four Body Regions: Analysis from the Heads Up StudyJacob P Thyssen, David Rosmarin, Antonio Costanzo, et al.
Dermatology and Therapy|July 7, 2022
Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-AnalysisApril Armstrong, Kyle Fahrbach, Craig Leonardi, et al.
JAAD International|July 23, 2024
Developing a questionnaire for assessing clinician- and patient-reported outcomes in actinic keratosis: Results from an expert panelBrian Berman, April Armstrong, Mark Lebwohl, et al.
Pageof 13